6CM
MAIA icon

683 Capital Management’s MAIA Biotechnology MAIA Stock Holding History

683 Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Hold
1,066,666
– – 0.08% 114
2026
Q1 		$1.49M Buy
+1,066,666
New +$1.97M 0.08% 126

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

683 Capital Management's MAIA Position: Q2 2026 in Review

683 Capital Management held its MAIA Biotechnology (MAIA) position steady in Q2 2026 at 1,066,666 shares worth $1.54M. The position accounts for 0.08% of the portfolio, ranked #114.

683 Capital Management first reported a position in MAIA in Q1 2026 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • 683 Capital Management held 1,066,666 shares of MAIA Biotechnology worth $1.54M as of Q2 2026.
  • 683 Capital Management left its MAIA Biotechnology share count unchanged in Q2 2026.
  • MAIA Biotechnology made up 0.08% of 683 Capital Management's portfolio in Q2 2026, its #114 holding.
  • 683 Capital Management first reported a position in MAIA Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.